Resumen
Lamotrigina es una molécula relativamente reciente en el tratamiento de epilepsia. Este medicamento ha mostrado efectividad aceptable en crisis epilépticas de múltiples etiologías. Presentamos una revisión no sistemática con respecto a lamotrigina y epilepsias generalizadas, reportando un perfil de seguridad aceptable con eficacia en el control de crisis cuando es suministrado como monoterapia o como tratamiento adjuyuvante.
Citas
William, F; Gidal, B. Lamotrigine. En Willie E, ed. The Treatment of Epilepsy. Baltimore: Lippincot William Wilkins; 2001: 933 – 939,
McNamara J. Fármacos eficaces en epilepsia. En: Hardman J, Limbird L, Molinoff P et al, eds. Goodman y Gilman: Las Bases Farmacológicas de la Terapéutica. México, D, F: McGraw Hill interamericana; 2003: 491 – 520.
Bialer M, Johannessen S, Kupferberg H, Levy R, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Research 2007; 73: 1 - 52.
Dreifuss F. Lamotrigine in Childhood Epilepsies. Seminars in Pediatric Neurology, 1997; 4: 19-23.
Farrell K, Connolly M, Munn R, et al. Prospective, Open-label, Add-on Study of Lamotrigine in 56 Children With Intractable Generalized Epilepsy. Pediat neurol 1997; 16: 201 -205.
Brodbeck V, Jansen V, Fietzek U, Muehe C, Weber G, Heinen F. Long-Term Profile Of Lamotrigine In 119 Children With Epilepsy. European Journal Of Paediatric Neurology 2006; 10: 135 – 141.
Morris G, Hammer A, Kustra R, Messenheimer J. Lam- otrigine for Patients with Juvenile Myoclonic Epilepsy Follow- ing Prior Treatment with Valproate: Results of an Open-label Study. Epilepsy & Behavior, 2004; 5: 509–512.
Dulac O, Plouin P, Shewmon A, Contributors to the Royaumont Workshop. Myoclonus and Epilepsy in Child- hood. Epilepsy Research, 1998; 30: 91–106.
Wallace S. Myoclonus and Epilepsy in Childhood: A review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Research, 1998; 29; 147–154.
Coppola G, Licciardi F, Sciscio N, Russo F, Carotenuto M, Pascotto A. Lamotrigine As First-Line Drug In Childhood Absence Epilepsy: A Clinical And Neurophysiological Study. Brain & Development, 2004; 26: 26–29.
Steinhoff B, Ueberall M.A, Siemes H, Kurlemann G, Schmitz B, Bergmann L. The LAM-SAFE Study: Lamotrigine Versus Carbamazepine Or Valproic Acid In Newly Diagnosed Focal And Generalised Epilepsies In Adolescents And Adults. Seizure, 2005; 14: 597- 605.
Besag F.M, Dulac O, Alvlng J y Mullens E. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997; 6: 51-56.
Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine Monotherapy in Children. Pediatr Neurol 2000; 23: 160-163.
Akman, I, Holmes GL. The Effect Of Lamotrigin On The Eegs Of Children And Adolescents With Epilepsy. Epilepsy & Behavior, 2003; 4:420-423.
Guidal BE, Tamura T., Hammer A., Vuong A. Blood Homocysteine, Folate And Vitamin B-12 Concentrations In Patients With Epilepsy Receiving Lamotrigine Or Sodium Valproate For Initial Monotherapy. Epilepsy Research 2005; 64: 161-166
Betts T, Yarrow H, Dutton N, Greenhill L y Rolfe T. A Study Of Anticonvulsant Medication On Ovarian Function In A Group Of Women With Epilepsy Who Have Only Ever Taken One Anticonvulsant Compared With A Group Of Women Without Epilepsy. Seizure 2003; 12: 323–329
French J.A, Kanner A.M, Bautista J, et al, Efficacy And Tolerability Of The New Antiepileptic Drugs II: Treat- ment Of Refractory Epilepsy: Report Of The Therapeutics And Technology Assessment Subcommittee And Quality Standards Subcommittee Of The American Academy Of Neurology And The American Epilepsy Society. Neurology 2004; 62: 1261–1273
French J.A, Kanner A.M, Bautista J, et al. Efficacy And Tolerability Of The New Antiepileptic Drugs I: Treat- ment Of New Onset Epilepsy: Report Of The Therapeutics And Technology Assessment Subcommittee And Quality Standards Subcommittee Of The American Academy Of Neurology And The American Epilepsy Society. Neurology 2004; 62: 1252-1260
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.